Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Short term Debt (2025)

Apellis Pharmaceuticals filings provide 1 years of Short term Debt readings, the most recent being $93.7 million for Q4 2025.

  • For the quarter ending Q4 2025, Short term Debt changed N/A year-over-year to $93.7 million, compared with a TTM value of $93.7 million through Dec 2025, changed N/A, and an annual FY2025 reading of $93.7 million, changed N/A over the prior year.
  • Short term Debt hit $93.7 million in Q4 2025 for Apellis Pharmaceuticals, roughly flat from $93.6 million in the prior quarter.
  • The five-year high for Short term Debt was $93.7 million in Q4 2025, with the low at $93.6 million in Q3 2025.